Last reviewed 2026-06-10 · How we verify

Advanced BRCA-mutated or HDR-deficient breast cancer — Treatment Landscape & Competitive Intelligence

Advanced BRCA-mutated or HDR-deficient breast cancer (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Advanced BRCA-mutated or HDR-deficient breast cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Duke University · 1 drug in Advanced BRCA-mutated or HDR-deficient breast cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced BRCA-mutated or HDR-deficient breast cancer:

• Advanced BRCA-mutated or HDR-deficient breast cancer treatment updates — RSS
• Advanced BRCA-mutated or HDR-deficient breast cancer treatment updates — Atom
• Advanced BRCA-mutated or HDR-deficient breast cancer treatment updates — JSON

Cite this brief

Drug Landscape (2026). Advanced BRCA-mutated or HDR-deficient breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-brca-mutated-or-hdr-deficient-breast-cancer. Accessed 2026-06-10.

Related

• Advanced BRCA-mutated or HDR-deficient breast cancer full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing